BTG3 and preeclampsia: Stratified univariate analysis indicated that HCQ use in the ANA-positive group significantly reduced the incidence of preeclampsia (2.13% vs. 27.27%, p = 0.019) and prolonged gestation (38.29 ± 2.54 vs. 34.48 ± 7.68 weeks, p = 0.006).